Articles from DIAGONAL THERAPEUTICS, INC

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study

WATERTOWN, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, today announced the publication of study results detailing new health economics and outcomes research (HEOR) that characterizes the significant healthcare utilization and costs associated with hereditary hemorrhagic telangiectasia (HHT) in the American Journal of Hematology.

Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH)

DIAG723 is supported by a groundbreaking preclinical profile demonstrating its disease-modifying potential

Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated anemia

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT

– Study finds annual healthcare costs per patient are significantly higher than previously described

Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)

- DIAGONAL platform, combining proprietary computational and experimental techniques to identify rare agonist antibodies that reactivate deficient signaling pathways, has generated a pipeline of novel therapeutics